UPCOMING LECTURES

PUBLICATIONS

Currently none available

CRISPR/Cas9 and drug screening in GBM patient-derived models

We are determining the functional roadmap for each of the PDCLs by investigating both genetic and therapeutic dependencies. By using a combination of drug screening and genetic editing approaches, using state-of-the-art technologies (including Crispr/Cas9 editing), we are searching for the primary driver events the cause aberrant cell growth.

By using CRISPR/Cas9 gene targeting we can identify potential targets that make the tumor cells of a patient susceptible for therapy. This done using “drop-out” screens in a targeted way.

We optimized SOPs to perform high quality drug screening on all our available patient-derived cell lines. This includes the standard of care for GBM (Radiation therapy, Temozolomide), but also experimental drugs.

SHARE THIS PAGE